Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization

Narita, Michiko; Oussoultzoglou, Elíe; Chenard, Marie–Pierre; Rosso, Edoardo; Casnedi, Selenia; Pessaux, Patrick; Bachellier, Philippe; Jaeck, Daniel

doi:10.1007/s00595-010-4414-x

Cited by 47 publications

(37 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, oxaliplatin and irinotecan were reported to induce severe liver injury known as sinusoidal obstruction syndrome and steatohepatitis, respectively, and to impair liver regeneration [12,22,23]. Additionally, in the present study, a history of chemotherapy containing these drugs was indicated as a strong negative predictive factor (regression coefficient: −21.2).…”

Section: Discussionmentioning

confidence: 68%

“…Previous PVE studies demonstrated that FLR volume increased by 20-50% within a 3- to 7-week interval between PVE and hepatectomy [5,6,7,8]. However, various conditions, including hepatitis, cholestasis, and chemotherapy, are reported to affect remnant liver hypertrophy [7,9,10,11,12]. Meanwhile, 10-20% of the cases become unresectable after such an interval because of tumor progression or insufficient remnant liver hypertrophy [13,14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prediction of the Remnant Liver Hypertrophy Ratio after Preoperative Portal Vein Embolization

Kasai¹,

Hatano²,

Iguchi³

et al. 2013

Eur Surg Res

View full text Add to dashboard Cite

Background: Portal vein embolization (PVE) is considered to improve the safety of major hepatectomy. Various conditions might affect remnant liver hypertrophy after PVE. The aim of the present study was to clarify the factors that affect remnant liver hypertrophy and to establish a prediction formula for the hypertrophy ratio. Methods: Fifty-nine patients who underwent preoperative PVE for cholangiocarcinoma (39 patients), metastatic carcinoma (10 patients), hepatocellular carcinoma (8 patients), and other diseases (2 patients) were enrolled in this study. For the prediction of the hypertrophy ratio, a formula with stepwise multiple regression analysis was set up. The following parameters were used: age, gender, future liver remnant ratio to total liver (FLR%), plasma disappearance rate of indocyanine green (ICGK), platelet count, prothrombin activity, serum albumin, serum total bilirubin at the time of PVE and the maximum value before PVE (Max Bil), as well as a history of cholangitis, diabetes mellitus, and chemotherapy. Results: The mean hypertrophy ratio was 28.8%. The 5 parameters detected as predictive factors were age (p = 0.015), FLR% (p < 0.001), ICGK (p = 0.112), Max Bil (p < 0.001), and history of chemotherapy (p = 0.007). The following prediction formula was established: 101.6 - 0.78 × age - 0.88 × FLR% + 128 × ICGK - 1.48 × Max Bil (mg/dl) - 21.2 × chemotherapy. The value obtained using this formula significantly correlated with the actual value (r = 0.72, p < 0.001). A 10-fold cross validation also showed significant correlation (r = 0.62, p < 0.001), and a hypertrophy ratio <20% was predictable with a sensitivity of 100% and a specificity of 90.9%. Moreover, technetium-99m-diethylenetriaminepentaacetic acid-galactosyl human serum albumin scintigraphy showed a significantly smaller increase in the uptake ratio of the remnant liver in patients with prediction values <20% than in those with values ≥20% (6.8 vs. 20.8%, p = 0.030). Conclusions: The prediction formula can prognosticate the hypertrophy ratio after PVE, which may provide a new therapeutic strategy for major hepatectomy.

show abstract

Section: Discussionmentioning

confidence: 68%

Section: Introductionmentioning

confidence: 99%

Prediction of the Remnant Liver Hypertrophy Ratio after Preoperative Portal Vein Embolization

Kasai¹,

Hatano²,

Iguchi³

et al. 2013

Eur Surg Res

View full text Add to dashboard Cite

show abstract

“…Whereas 16 SD seems to have a clear inhibitory effect on hypertrophy [126], chemotherapy has no effect on liver regrowth [121,127]. Moreover, patients with NASH show a trend towards less post-PVE liver volume gain compared to patients with normal liver function [126].…”

Section: Enlarging Of Future Remnant Liver Volumementioning

confidence: 97%

Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure

Mierlo

Schaap

Dejong

et al. 2016

Journal of Hepatology

103

View full text Add to dashboard Cite

show abstract

“…40 Several studies have associated sinusoidal injury and steatohepatitis with compromised liver regeneration as well as increased morbidity following hepatic resection. [41][42][43][44] …”

Section: Liver-related Factorsmentioning

confidence: 98%

Defining Post Hepatectomy Liver Insufficiency: Where do We stand?

Lafaro

Buettner

Maqsood

et al. 2015

Journal of Gastrointestinal Surgery

103

View full text Add to dashboard Cite

show abstract

Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization

Abstract: Sinusoidal obstruction syndrome inhibits FRL hypertrophy after PVE and induces postoperative liver failure. Therefore, an alternative strategy is needed to perform TSH safely in the presence of SOS.

Cited by 47 publications

References 35 publications

Prediction of the Remnant Liver Hypertrophy Ratio after Preoperative Portal Vein Embolization

Prediction of the Remnant Liver Hypertrophy Ratio after Preoperative Portal Vein Embolization

Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure

Defining Post Hepatectomy Liver Insufficiency: Where do We stand?

Contact Info

Product

Resources

About